<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00406068</url>
  </required_header>
  <id_info>
    <org_study_id>HIS-0611-0602</org_study_id>
    <nct_id>NCT00406068</nct_id>
  </id_info>
  <brief_title>Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer</brief_title>
  <official_title>Open-label, Multi-center Study of the Efficacy and Safety of MCC in the Treatment of Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Progression and Who Are Refractory to BCG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioniche Life Sciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioniche Life Sciences Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of intravesical
      Mycobacterial Cell Wall-DNA Complex (MCC) in patients with non-muscle invasive transitional
      cell carcinoma (papillary tumors and/or carcinoma in situ) of the urinary bladder at high
      risk of progression who are refractory to therapy with bacillus Calmette-Guerin (BCG).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be divided into 3 phases: Induction, Maintenance, and Follow-up.

      The Induction Phase will cover a period of 6 weeks. During this time, patients will receive 6
      weekly intravesical instillations of 8 mg MCC. The patients will be evaluated at month 3, at
      which time the patients will enter the Maintenance Phase. The Maintenance Phase will last
      from month 3 to month 24, and during this time, patients will receive weekly MCC
      instillations for three weeks at months 3, 6, 12, 18, and 24 and evaluations will be
      performed at months 3, 6, 9, 12, 15, 18, 21 and 24.

      At month 3, the patient will be evaluated to assure that the disease is not progressing.
      Cytology, cystoscopy and biopsies will be performed to obtain adequate staging (if residual
      tumor persists). If the patient is disease-free, maintenance therapy will be initiated.
      Patients with non-muscle invasive tumors at month 3 will, at the discretion of the
      investigator, receive either a second 6-week induction course or a 3-week maintenance course.
      Patients who show progression to muscle invasive disease will be referred to other
      treatments.

      At month 6 and thereafter at each evaluation visit, patients will be evaluated and managed
      according to the following results:

        -  Patients who are disease-free will continue on maintenance treatment.

        -  Patients who are not disease-free (evidence of papillary lesions, CIS or muscle invasive
           disease) will be withdrawn from further study treatment and will be referred to other
           therapies at the discretion of the investigator.

      The final 36 months of the study is the Follow-up Phase. Evaluations will be performed at
      months 30, 36, 42, 48, 54 and 60.

      Efficacy evaluations will include standard cystoscopy, biopsies and urine cytology. During
      the Maintenance Phase, standard cystoscopies will be performed at months 3, 6, 9, 12, 15, 18,
      21 and 24 for the surveillance of bladder tumors. During the months that instillations will
      be performed, cystoscopies will be conducted only once at each of these months. During the
      Follow-up Phase, cystoscopies will be performed at months 30, 36, 42, 48, 54 and 60.

      Mandatory bladder biopsies will be done for all patients at month 6.

      During the course of the study, biopsies will be taken only if evident or suspicious lesions
      are seen during cystoscopy or in case of negative cystoscopy but positive cytology.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>One year disease-free survival rate</measure>
    <time_frame>Prospective</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The 3, 6 and 24 month disease-free survival rate</measure>
    <time_frame>Prospective</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of disease-free survival in all patients</measure>
    <time_frame>Prospective</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression to muscle invasive disease</measure>
    <time_frame>Prospective</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in all patients</measure>
    <time_frame>Prospective</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of overall drug-related adverse events leading to two consecutive treatment delays of one week each or to the discontinuation of treatment.</measure>
    <time_frame>Prospective</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Bladder Neoplasms</condition>
  <arm_group>
    <arm_group_label>Mycobacterial cell wall-DNA complex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mycobacterial cell wall-DNA complex</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycobacterial cell wall-DNA complex</intervention_name>
    <description>8 mg MCC, intravesical - Induction Phase (6 weekly intravesical instillations) and Maintenance Phase (3 weekly instillations at months 3, 6, 12, 18 and 24).</description>
    <arm_group_label>Mycobacterial cell wall-DNA complex</arm_group_label>
    <other_name>MCC - Urocidin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients refractory to BCG therapy;

          -  Patients with histologically confirmed diagnosis of high grade lesions;

          -  Diagnosis of high grade lesion must be within 56 days prior to beginning of study
             treatment;

          -  Have had all visible papillary lesion(s) resected by TURBT within 56 days prior to
             beginning of study treatment;

          -  Available for the whole duration of the study including follow-up (60 months);

          -  Life expectancy of &gt; 5 years;

          -  Patients with an ECOG performance status grade of 2 or less;

          -  Absence of urothelial carcinoma involving the upper urinary tract or prostatic urethra
             within 12 months from beginning of study treatment;

          -  Able to understand and give written informed consent;

          -  In the investigator's judgment, the patient is able to participate in the study.

        Exclusion Criteria:

          -  Current or previous history of muscle invasive tumors;

          -  Current or previous history of lymph node or distant metastases from bladder cancer;

          -  Current systemic cancer therapy;

          -  Current or prior pelvic external beam radiotherapy;

          -  Pelvic brachytherapy within 2 years of study entry;

          -  Prior treatment with MCC;

          -  Patients with existing urinary tract infection or recurrent severe bacterial cystitis;

          -  Clinically significant and unexplained elevations of liver or renal function tests;

          -  White blood cell count below 3 x109/L (3,000/mm3) or platelet count below 100 x
             109/L(100,000/mm3);

          -  Severe cardiovascular disease;

          -  Women who are pregnant or lactating;

          -  Congenital or acquired immune deficiency;

          -  With history of malignancy of any organ system, treated or untreated, within the past
             5 years (with the exception of adequately treated basal cell or squamous cell
             carcinoma of the skin, stage T1 prostate cancer, carcinoma in situ of the cervix or
             colon polyps);

          -  Previous investigational treatment within 3 months from beginning of study treatment;

          -  Patients who cannot hold the instillation for one hour;

          -  Patients who cannot tolerate intravesical administration or intravesical surgical
             manipulation (cystoscopy or biopsy);

          -  Clinically significant active infections;

          -  Any medical or psychiatric condition which, in the opinion of the investigator, would
             preclude the participant from adhering to the protocol or completing the trial per
             protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alvaro Morales, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Applied Urological Research, Kingston General Hospital/Queen's University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BCG Oncology</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Clinical Trials</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Urological Research at Grove Hill</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winter Park Urology Associates P.A.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Hospitals</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Welborn Clinic</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheldon J Freedman, MD, Ltd</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Valley Urology, LLC-Voorhees</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Centre</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudson Valley Urology</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triangle Urology Group</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Clinics of North Texas, P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio Research, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Medical Group - Urology of Virginia, PC</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andreou Research</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Can-Med Clinical Research</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 5G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Steinhoff Clinical Research</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Applied Urological Research</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network / Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Male Health Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6A 3B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche du CHUQ</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://dx.doi.org/10.1016/j.juro.2014.09.109</url>
    <description>Publication that includes results for this study.</description>
  </link>
  <results_reference>
    <citation>Morales A, Herr H, Steinberg G, Given R, Cohen Z, Amrhein J, Kamat AM. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Gu√©rin. J Urol. 2015 Apr;193(4):1135-43. doi: 10.1016/j.juro.2014.09.109. Epub 2014 Oct 5.</citation>
    <PMID>25286009</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2006</study_first_submitted>
  <study_first_submitted_qc>December 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <disposition_first_submitted>August 28, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>August 28, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 12, 2013</disposition_first_posted>
  <last_update_submitted>July 26, 2016</last_update_submitted>
  <last_update_submitted_qc>July 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bladder neoplasm</keyword>
  <keyword>Intravesical drug administration</keyword>
  <keyword>Neoplasm recurrence, local</keyword>
  <keyword>Transitional cell, carcinoma</keyword>
  <keyword>Carcinoma in situ</keyword>
  <keyword>Mycobacterium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

